A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11931 participants.

Also called NCT04126486

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 11,931 participants (enrolled count) (from the registry)
Sponsor
  • Bristol-Myers Squibb Registry lists this organization as the lead sponsor
  • Pfizer Registry lists this organization as a collaborator
Registry
  • NCT NCT04126486
Other papers using this trial's data
  • Atrial Fibrillation Burden on a 14-Day ECG Monitor: Findings From the GUARD-AF Trial Screening Arm JACC. Clinical electrophysiology, 2025-01 DOI, PubMed 39297839
  • Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention Journal of the American College of Cardiology, 2024-11-19 DOI, PubMed 39230544

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04126486. Randomized; no masking; primary purpose prevention. Start 2019-12-17 (actual); primary completion 2023-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke
Acronym
GUARD-AF
Intervention (Other)
Zio®XT Monitor
Lead sponsor
Bristol-Myers Squibb (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct04126486
Content hash
bb00ff29010da4c9f40e66cc35de0cad4743b5a832907fb17d3c1c5e0763cc9e